Education
About Us
Working with TipRanks
Follow Us
Evolent Health (EVH)
NYSE:EVH
EVH Stock Chart & Stats
$2.67
<$0.01(0.08%)
At close: 4:00 PM EST
$2.67
<$0.01(0.08%)
Day’s Range― - ―
52-Week Range$2.50 - $12.07
Previous CloseN/A
Volume268.11K
Average Volume (3M)3.23M
Market Cap
$298.07M
Enterprise Value$1.14B
Total Cash (Recent Filing)$151.86M
Total Debt (Recent Filing)$989.70M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
May 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding111,638,336
10 Day Avg. Volume2,832,759
30 Day Avg. Volume3,231,820
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market Cap3.84
Enterprise Value/Revenue0.61
Enterprise Value/Gross Profit4.04
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$5.58Price Target Upside108.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)0.14
Revenue Forecast (FY)$2.49B
Bulls Say, Bears Say
Bulls Say
Conservative Guidance And Valuation UpsideConservative reserve booking and clarified revenue guidance reduce downside risk and, if actual contract impacts prove smaller than assumed, could unlock earnings upside and support valuation expansion given the company's growth profile.
Margin Improvement And Operational EfficiencyMaturing Performance Suite contracts, realized cost controls, and AI-driven efficiencies are expected to reduce result volatility and improve adjusted EBITDA as the book of business matures.
New Contracts And PipelineLarge managed-care contract wins and a robust late-stage sales pipeline improve revenue visibility and help offset revenue lost from divestitures and client changes, supporting future top-line growth.
Bears Say
Execution Risk And Balance Sheet PressureInconsistent execution and weaker profitability guidance, combined with expectations of rising debt before improvement, raise concerns about the timing of profit recovery and balance-sheet normalization.
Membership Losses And Enrollment DeclineChurn and declining exchange enrollment related to subsidy and plan changes are reducing revenue stability and weighing on earnings for segments exposed to those markets.
Reserve-driven Margin DragUpfront reserves tied to new performance-oriented contracts and higher medical expense assumptions create a short-term margin drag that can reduce reported profitability before reserves are released.
Evolent Health News
EVH FAQ
What was Evolent Health’s price range in the past 12 months?
Evolent Health lowest stock price was $2.50 and its highest was $12.06 in the past 12 months.
What is Evolent Health’s market cap?
Evolent Health’s market cap is $298.07M.
When is Evolent Health’s upcoming earnings report date?
Evolent Health’s upcoming earnings report date is May 06, 2026 which is in 47 days.
How were Evolent Health’s earnings last quarter?
Evolent Health released its earnings results on Feb 24, 2026. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.051 by $0.029.
Is Evolent Health overvalued?
According to Wall Street analysts Evolent Health’s price is currently Undervalued.
Does Evolent Health pay dividends?
Evolent Health does not currently pay dividends.
What is Evolent Health’s EPS estimate?
Evolent Health’s EPS estimate is -0.05.
How many shares outstanding does Evolent Health have?
Evolent Health has 111,638,336 shares outstanding.
What happened to Evolent Health’s price movement after its last earnings report?
Evolent Health reported an EPS of $0.08 in its last earnings report, beating expectations of $0.051. Following the earnings report the stock price went up 22.656%.
Which hedge fund is a major shareholder of Evolent Health?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.58 (108.99% Upside)
$5.58 (108.99% Upside)
Blogger Sentiment
Neutral
EVH Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 420.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.66%
12-Months-Change
Fundamentals
Return on Equity
-69.22%
Trailing 12-Months
Asset Growth
-25.36%
Trailing 12-Months
Company Description
Evolent Health
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
EVH Company Deck
EVH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: strong top-line growth prospects (mid-2026 revenue growth target ~30%), large new Performance Suite contracts (including a significant Highmark engagement), solid 2025 MER improvement and realized cost/AI savings support long-term margin tailwinds. However, near-term headwinds are meaningful — conservative reserving for new launches (new cohort at ~103% MER), a $40M exchange-related revenue/EBITDA hit from regulatory/market shifts, administrative churn and limited free cash flow in 2026. Management emphasized that 2026 adjusted EBITDA will be back-end weighted and articulated a clear path to improved margins and cash flow as contracts mature, supporting a balanced long-term outlook despite near-term pressure.View all EVH earnings summariesEVH Stock 12 Month Forecast
Average Price Target
$5.58
▲(108.99% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---